JeanMarie Guenot graduated from Wharton School of business with an MBA. She went on to receive a Ph.D. from the University of California, San Francisco. She is a business executive who has over 20 years of experience in the biotechnology and pharmaceutical industry. JeanMarie Guenot currently is the CEO and President of Amphivena Therapeutics, Inc. Amphivena technologies on guenotllc.com. The company works with developing bifunctional antibody therapies for hematologic disorders. Their work with immunotherapy and leukemia has shown positive results.
The sphere of blood diseases has a high need for development and new technology.
JeanMarie Guenot has worked with companies in all stages of development in the public and the private sector. Before her current role, Guenot worked with SKS Ocular which specialized in ophthalmics. She founded, ran, and built that company.
Her prior experience in biotechnology and pharmacy includes working with PDL BioPharma, where she was Vice President of Corporate & Business Development. There they developed treatments for Phase 2 cancer and autoimmunology disease drug candidates. In 2005, JeanMarie Guenot received the Innovative Bio-Partnering Award from BioBusiness. Her work in oncology spans years. She began her career as a preclinical scientist at R&D at Hoffmann-La Roche developing medicines for cancer, autoimmune diseases, and inflammation.
Learn more about Jeanmarie Guenot: http://www.businesswire.com/news/home/20170111005414/en/Maverick-Therapeutics-Takeda-Announce-Five-year-Collaboration-Advance